Considering the FGFR1 related leukemia are driven by both the full-length fusion kinase and the truncated tnFGFR1, we examined the long-term efficacy of the combination of FLT3 and FGFR1 inhibitors with our SCLL leukemia model. The gene discussed is FGFR1; the disease is leukemia.